Are CagriSema's REDEFINE-2 trial results concerning? Perhaps not
11/03/25 -"Novo’s investors appeared worried yesterday after its promising obesity/diabetes drug candidate, CagriSema’s, another late-stage trial results yielded weight-loss efficacy which was ..."
Pages
77
Language
English
Published on
11/03/25
You may also be interested by these reports :
19/12/25
The change in the target price is due to a change in the analyst covering the stock, complemented by the usage of systematic intrinsic and peer-based ...
17/12/25
Since Bayer’s shares have already surged 87% ytd, recovering to their highest levels in the last two years, we do not foresee a material upside ...
12/12/25
Eli Lilly’s Retatrutide grabbed headlines with c.29% weight-loss efficacy in late-stage trials for obese patients who also had knee osteoarthritis. ...
08/12/25
Despite US tariff threats, drug pricing pressures and the persistent insistence from the US government to reshore manufacturing, the AV Big Pharmas ...